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I M M U N O L O G Y
Graphene quantum dots as anti-inflammatory therapy 
for colitis
Byung-Chul Lee1*†, Jin Young Lee1*‡, Juhee Kim2, Je Min Yoo2§, Insung Kang1, Jae-Jun Kim1, 
Nari Shin1, Dong Jin Kim3, Soon Won Choi1, Donghoon Kim4, Byung Hee Hong2,4,5||, Kyung-Sun Kang1||
While graphene and its derivatives have been suggested as a potential nanomedicine in several biomimetic mod-
els, their specific roles in immunological disorders still remain elusive. Graphene quantum dots (GQDs) may be 
suitable for treating intestinal bowel diseases (IBDs) because of their low toxicity in vivo and ease of clearance. 
Here, GQDs are intraperitoneally injected to dextran sulfate sodium (DSS)–induced chronic and acute colitis model, 
and its efficacy has been confirmed. In particular, GQDs effectively prevent tissue degeneration and ameliorate 
intestinal inflammation by inhibiting TH1/TH17 polarization. Moreover, GQDs switch the polarization of macrophages 
from classically activated M1 to M2 and enhance intestinal infiltration of regulatory T cells (Tregs). Therefore, GQDs 
effectively attenuate excessive inflammation by regulating immune cells, indicating that they can be used as 
promising alternative therapeutic agents for the treatment of autoimmune disorders, including IBDs.
INTRODUCTION
Intestinal bowel diseases (IBDs) including Crohn’s disease and ul-
cerative colitis are destructive, relapsing tissue disorders that involve 
dysregulation of the local immune response and compromised intes-
tinal barrier function (1). The pathophysiology of IBDs is associated 
with exaggerated T cell responses (2) and related macrophages, which 
are one of the most abundant myeloid cells in the peritoneal cavity, 
including intestinal mucosa. The extensive interactions between T cells 
and macrophages deteriorate inflammation. Therefore, understanding 
the mechanism of macrophage’s regulation on T cell differentiation is 
essential in developing previously unidentified therapeutics for IBDs. 
Many approaches have been made to find a way to cure IBDs, and al-
ternative therapeutics are in urgent need as the disease prevails through-
out the world (3). Although the use of immunosuppressive drugs is 
one of the main treatments (4) and methods to increase the drug de-
livery to lesion have also been developed (5), the treatments for IBDs 
are often accompanied by complications such as infections and malig-
nancies (6). Thus, alternative drug with less side effects is still needed. 
Recent studies have suggested suitable mouse models for Crohn’s dis-
ease by introducing genetic modifications and particular microor-
ganisms (7). Nevertheless, impaired intestinal barrier function and 
subsequent dysregulated immune response are still considered as 
a crucial factor for disease onset (1). To address this issue, we tried 
graphene quantum dots (GQDs) as therapeutics in colitis model mice 
because previous research has shown that graphene derivatives in-
teract with immune cells including macrophages and T cells (8).
Graphene derivatives, especially GQDs, have high biocompatibility 
and antioxidant effect, so GQDs have been exploited as a potential 
therapeutic agent for treating inflammatory diseases (9). GQDs can 
scavenge reactive oxygen radicals by delocalizing electron density in 
the conjugated ring structure; hence, they are able to reduce oxidative 
stress. Besides, there are abundant anionic functional groups on the 
edges, in which the property is known to provoke fewer immune re-
sponses compared to positively charged nanoparticles (10). In addi-
tion, previous studies showed the potential uses of graphene materials 
in vaccines, immunotherapeutics, and immunosuppressive agents 
(11). However, there are few reports on graphene material’s roles in 
autoimmune diseases including IBDs.
IBDs have frequently been studied using the dextran sulfate sodium 
(DSS) colitis animal model due to its simplicity, reproducibility, and 
rapidity (12). Notably, the clinical and histological features of DSS- 
induced animals are very similar to those observed in human patients. 
DSS disrupts colonic epithelium, leading to the entry of luminal bacteria 
and antigens into the mucosa and resulting in stimulation of immune 
cells and secretion of proinflammatory cytokines and chemokines 
(13). Furthermore, a polarized T helper 1 (TH1) response and proin-
flammatory macrophages have been reported to aggravate the inflam-
matory response in DSS colitis model. For these reasons, we used the 
DSS colitis model to identify the inhibitory effects of GQDs on acute 
and chronic colitis.
Our previous study showed that GQDs have protective effects 
on Parkinson’s disease by direct interaction with -synuclein fibrils 
without toxicity and can be excreted by urine (14). In this study, we 
also confirmed the therapeutic effects of GQDs on colitis model mice 
without any complications. The ex vivo and in vitro analyses were 
proceeded to investigate the underlying mechanisms of the therapeutic 
effects of GQDs, which regulated T cell and macrophage subsets to 
facilitate the disease recovery.
RESULTS
Characterization of GQDs
GQDs were synthesized by the improved Hummer’s method accord-
ing to the previous literature (fig. S1A) (15). Transmission electron 
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microscopy (TEM) image showed the lateral size distribution of the 
GQDs, which had an average size of 28.5 ± 9.7 nm (fig. S1B). The 
height of the synthesized GQDs was determined by atomic force mi-
croscopy (AFM), which showed 7.1 ± 1.8 nm (fig. S1C). The properties 
of GQDs were further determined by Raman spectroscopy (fig. S1D), 
exhibiting distinctive D and G bands at 1360 and 1600 cm−1, which 
are the characteristic peaks of graphene-based materials. GQDs dis-
played intense and broad D band, which arose from the presence of 
many defect sites. Functional groups of GQDs were verified by Fourier- 
transform infrared spectroscopy (FT-IR), elemental analysis (EA), 
and x-ray photoelectron spectroscopy (XPS). The major peaks from 
the FT-IR (fig. S1E) spectrum of GQDs were O─H (3430 cm−1), 
C═O (1730 cm−1), C═C (1620 cm−1), and C─O (1220 cm−1), show-
ing the presence of hydroxyl, carboxyl groups, and epoxide rings. 
Successful coupling of biotin was proved by the appearance of new 
peaks at 1400 cm−1 (C─H) and at 1080 cm−1 (C─O), both derived 
from polyethylene glycol (PEG). More intense transmittance was ob-
served around 3420 and 1610 cm−1 due to the newly formed amide 
bond. The ratio of oxygen to carbon of GQDs was measured by EA 
(table S1), and the value 0.73 showed the highly oxidized state of 
graphite. Through XPS (fig. S1F), the binding energy of C─C (284.50 eV), 
C─O (286.68 eV), and C═O (288.36 eV) bonds was measured. The 
C─C bond showed the highest content of 50.54%, and the percent-
age of C─O and C═O was 38.21 and 11.25%, respectively. The sur-
face charge of GQDs was evaluated by zeta potential, in which the 
measured value −52.2 ± 6.85 mV showed a highly negatively charged 
surface and well-dispersed property. On the basis of the measured 
properties of GQDs, we sought to explore the impact of its therapeutic 
effects against DSS-induced mice.
GQDs ameliorate DSS-induced colitis in mice
To investigate the therapeutic efficacy of GQDs against IBDs, we 
established chronic and acute colitis models using DSS (Figs. 1A 
and 2A). DSS-induced colitis mice were intraperitoneally injected 
with GQDs after the induction of colitis, and the body weight, sur-
vival rate, and disease activity of the mice were monitored. The treat-
ment of GQDs increased survival rates (Fig. 2B) and reduced loss of 
body weight (Figs. 1B and 2C) in both models, suggesting a probabil-
ity of the amelioration of the disease. Consistent with the results, the 
disease activity index (DAI) values were significantly decreased in the 
presence of GQDs (Figs. 1C and 2D). The shortening of the colon, 
which is the characteristic pathological feature of colitis, was substan-
tially inhibited as well (Figs. 1D and 2E). Myeloperoxidase (MPO) 
level, a commonly used biomarker of colitis, is a neutrophil granule 
constituent, where its level is proportional to the number of migrated 
neutrophils. In the GQD-treated group, the MPO activity in colon 
tissues decreased by 45% compared to the phosphate-buffered saline 
(PBS)–treated mice, implying that GQDs suppressed the infiltration of 
neutrophils (Fig. 2F). Histological analysis also showed the inhibitory 
effect of GQDs on colonic inflammation, which exhibited retainment 
of the intestinal epithelium and less infiltration of immune cells. From 
picrosirius red and Masson’s trichrome staining, the generation of 
fibrotic tissues was reduced in both models (Figs. 1E and 2G). The 
secretion of interferon- (IFN-), the major cytokine involved in IBDs, 
was markedly reduced in the GQD-treated mice (Figs. 1F and 2H). 
Besides, in the presence of GQDs, the level of other proinflammatory 
cytokines—tumor necrosis factor– (TNF-), interleukin-6 (IL-6), and 
MCP-1—was also decreased. Collectively, GQDs showed preventive 
and therapeutic effects in both acute and chronic colitis models.
GQDs do not exert toxic effects on general health and are 
naturally excreted
After the sacrifice of colitis-induced mice, we observed an accumu-
lation of GQDs in the abdominal cavity, particularly on greater 
omentum and mesentery near spleen and colon (fig. S2). To assess 
the toxicity and excretion of GQDs, we monitored the general health 
conditions of the mice until 16 weeks from GQD injection. The body 
weights, as well as the consumption of water and food, were not sig-
nificantly different compared to those of the control group (Fig. 3, 
A and B). Also, a negligible difference was found between the weights 
of organs (Fig. 3C).
To determine whether GQDs could affect the immune system, 
proportions of immune cells in the spleen were assessed. GQDs did 
not change the immune cell proportions (fig. S3), and dysregulated 
immune reaction did not occur until 16 weeks based on the level of 
inflammatory cytokines measured (fig. S4). The concentration of IL-6, 
MCP-1, and TNF- in serum immediately increased at 2 hours after 
the injection. However, the levels of these cytokines were stabilized 
by day 1, and similar levels were maintained with the control group.
In addition to the general health status of the mice, we injected 
biotin-labeled GQDs and assessed its fate using a fluorescein iso-
thiocyanate (FITC)–conjugated anti-biotin antibody. Notably, the 
fluorescence in the abdominal mesentery gradually decreased with 
time, suggesting excretion of biotin-labeled GQDs (Fig. 3D). More-
over, as we reported in a previous article (14), intraperitoneally in-
jected GQDs were cleared out through urine despite their relatively 
larger size (Fig. 3E). A gradual decrease in the GQD concentration 
was observed over time, implying a successful excretion. Therefore, 
we concluded that the dosage and injection methods we used in the 
colitis model did not cause severe toxicity or disruption in the immune 
system in mice and that GQDs could be excreted out of the body.
GQDs potently inhibit the development of TH1 cells
The administration of GQDs to the DSS-induced colitis model in-
hibited the swelling of spleens (fig. S5A). Therefore, we sought to 
perform a set of ex vivo and in vitro analyses to discriminate the 
influences of GQDs on cells of the innate and adaptive immune sys-
tems. As TH1 cells secrete the major proinflammatory cytokine, IFN-, 
and play a crucial role in intestinal inflammation, we assessed the 
direct effect of GQDs on CD4+ T cells. GQDs decreased the number 
of TH1 cells in the spleen of the DSS-induced colitis model (Fig. 4A). 
IL-12, which promotes the differentiation of CD4+ T cells into TH1 
cells, was reduced as well, inhibiting the differentiation toward TH1 
cells (Fig. 4B).
To assess the direct effects of GQDs on T cells, human umbilical 
cord blood (hUCB)–derived CD4+ T cells were treated with various 
concentrations of GQDs to determine the optimal concentration, 
where GQDs (20 g/ml) effectively suppressed the proliferation of 
T cells (6 to 70%). Notably, GQDs contained the proliferation of pri-
mary CD4+ T cells and primary splenocytes (Fig. 4C and fig. S5B). 
Although no significant influence on the apoptotic pathway was ob-
served, GQDs managed to slightly increase the number of cells in the 
G1 cell cycle stage, suggesting a suppressed cell cycle progression 
(fig. S5, C and D). To investigate the direct effects of GQDs on TH1 
polarization, isolated naïve CD4+ T cells were differentiated into 
the TH1 cells in the presence of GQDs. GQDs reduced TH1 differen-
tiation (Fig. 4, D and E), and consistent results were found in the 
gene expression pattern (Fig. 4F). To analyze functional changes in 
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Fig. 1. Intraperitoneal injection of GQDs effectively alleviates DSS-induced chronic colitis in mice. (A) Experimental scheme for DSS-induced chronic colitis and 
GQD administration. DSS water (3.5%) was repetitively administered to mice to induce colitis. GQDs were injected intraperitoneally (300 g per head) 10 days after the 
administration of DSS. (B to F) Mice received intraperitoneal injection of GQDs after chronic DSS colitis induction. On day 27, mice were sacrificed for further investigation. 
(B) The percentage of body weight change and (C) the DAI for colitis severity were monitored for clinical assessment. (D) After 27 days from colitis induction, the lengths 
of the colons obtained from each group were measured. Photo credit: Byung-Chul Lee (Adult Stem Cell Research Center and Research Institute for Veterinary Science, 
College of Veterinary Medicine, Seoul National University). (E) Left: Representative images of colon sections stained with hematoxylin and eosin (H&E) and picrosirius red 
(PSR) staining for the assessment of histology and fibrosis. Scale bar, 200 m. Right: Histopathologic evaluations were conducted to examine lymphocyte infiltration and 
intestinal damage. Quantitative analysis of the fibrotic area (stained in red). (F) Serum was collected from the colitis mice, and the secreted levels of the indicated cytokines 
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Fig. 2. Intraperitoneal injection of GQDs suppresses DSS-induced acute colitis in mice. (A) Experimental scheme for acute colitis induction using DSS and administration 
of GQDs. (B to H) Mice received intraperitoneal injection of GQDs after acute DSS colitis induction. On day 14, mice were sacrificed for further investigation. (B) The survival 
rate and (C) percentage of body weight change were monitored for clinical assessment of colitis severity (N = 14 to 16 mice per group). (D) The DAI on day 10 were monitored. 
(E) Mice were sacrificed 14 days after the induction of colitis with DSS, and colon lengths were measured to determine intestinal damage. Photo credit: Byung-Chul Lee (Adult 
Stem Cell Research Center and Research Institute for Veterinary Science, College of Veterinary Medicine, Seoul National University). (F) The MPO level in the colon tissues was 
measured. (G) Left: Representative images of colon sections stained with H&E and Masson’s trichrome (MT) staining for the assessment of fibrosis. Scale bar, 200 m. Right: 
Histopathologic evaluations were conducted to assess lymphocyte infiltration and intestinal damage. Quantitative analysis of fibrotic area (stained in blue). (H) Serum was 
collected from the colitis mice, and the secreted levels of the indicated cytokines were assessed using CBA analysis (N = 5 mice per group). *P < 0.05, **P < 0.01, and 
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secreted in the cell culture supernatant (Fig. 4G). Proinflammatory 
cytokines (especially IL-2, IL-12, and IFN-) and transcription factor 
T-bet (TBX21), which have crucial roles in the lineage commitment of 
TH1 cells (16), and GQD treatment successfully lowered the cytokine 
levels and expression of TBX21. Therefore, GQDs alleviate colitis 
by not only suppressing the proliferation of CD4+ T cells but also 
restraining TH1 polarization.
GQDs increase Treg infiltration in vivo
Regulatory T cells (Tregs) protect tissues from robust inflammation 
and facilitate tissue healing by suppressing activated proinflammatory 
immune cells. Transforming growth factor–1 (TGF-1) and IL-10 
are major inducers and products of Tregs and play crucial roles in 
Treg-mediated colitis alleviation (17). We (18) and others (19) have 
previously demonstrated that the activation of Tregs accompanied 
recovery from experimental colitis. In line with this observation, 
the administration of GQDs increased the splenic polarization (fig. 
S6A) and colonic infiltration (Fig. 5, A and B, and fig. S6B) of the Treg 
population.
The secretion of TGF-1 (Fig. 5C) and IL-10 (Fig. 5D and fig. 
S6C) was increased by GQD treatment in the DSS-induced colitis 
model. Again, whether GQDs could directly affect the polarization 
of Tregs was verified. In the presence of GQDs, naïve CD4+ cells 
were induced toward the Treg lineage. Although GQDs did not 
increase the polarization of Treg (Fig. 5E), it enhanced the colonic 
and splenic infiltration of Tregs via increased IL-10 and TGF-1 
production.
Moreover, GQDs impeded the colonic infiltration of the mucosal 
effectors, TH17 cells (Fig. 5F), and their secretion of IL-17A (Fig. 5G), 
which have a pivotal role in onset and progression of IBDs (19, 20). 
The innate immune cell–derived cytokine IL-23, which is a promi-
nent inducer of TH17 polarization (21), was markedly diminished by 
GQD treatment (Fig. 5H). As shown in Figs. 1F and 2H, suppression 
of excessive inflammation was followed by a decrease of proinflam-
matory cytokines, including IL-6. In the presence of TGF-1, reduc-
tion of IL-6 and IL-23 could inhibit the generation of TH17 cells and 
accelerate compensatory Treg development, which leads to a resto-
ration of exaggerated inflammatory responses. Overall, the results 











































































































Fig. 3. GQDs are excreted from mice without generating toxicity. Without DSS induction, biotin-labeled GQDs were injected into normal mice by the same method 
and dosage, and monitored for 16 weeks (N = 5 mice per group). (A) Body weights and (B) water and food consumption were measured at each time point. (C) Mice were 
sacrificed at the indicated time points, and organ weights were assessed. (D) The FITC-labeled anti-biotin antibody was used to detect the presence of GQDs in the ab-
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indicate that GQDs increase the infiltration of Tregs and restore im-
mune balance in vivo without direct regulation of Tregs.
GQDs induce polarization toward M1 macrophages but 
subsequently convert to M2
Although an imbalance between the tolerogenic and protective im-
mune responses of intestinal macrophages elicits colonic inflamma-
tion (22), the symptoms of colitis can be relieved by alternatively 
activated M2-type macrophages, which have a role in recruiting Tregs 
and their secreted cytokines (23). Therefore, the effects of GQDs toward 
type-specific polarization of macrophage were investigated. GQDs 
induced naïve CD14+ cells to become more classical-type macro-
phages, M1, without any supplementary cytokines (fig. S7A). When 
CD14+ cells were induced to polarize to M1 in the presence of GQDs, 
although expression of CD86 was simultaneously elevated, GQDs 
managed to increase both the CD14+CD206+ and CD14+CD163+ pop-
ulations in M1-type cells (Fig. 6, A and B). Subsequent secretion of 
TNF- and IFN- was markedly decreased, indicating a reduced 
polarization of M1 macrophages (Fig. 6C). Moreover, GQD treat-
ment suppressed the mRNA levels of proinflammatory cytokines and 
the M1-specific transcription factor IRF5 (fig. S7B).
In the case of polarization toward M2, the expression of CD206 
on M2-type macrophages was decreased in the presence of GQDs 
(fig. S7A). The level of IL-10, the most prominent marker of M2 
macrophages, was increased; however, GQD treatment inhibited the 
expression of CLEC7A and IL-1ra, which are the genes related to M2a 
subtype (fig. S7B).
As macrophages are known to regulate differentiation of T cells, 
GQD-treated macrophages were cocultured with CD4+ T cells. As a 
result, the GQD-treated macrophages promoted the development 
of Tregs (Fig. 6D). Therefore, GQDs play a role in the resolution of 
inflammation by down-regulating the M1-like features of macro-
phages and converting them to anti-inflammatory M2 macrophages. 
This is possible as macrophages display distinctive plasticity and the 
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Fig. 4. GQDs suppress TH1-type immune responses. (A and B) Colons and serum samples were collected from chronic colitis–induced mice after administration of 
GQDs (N = 4 to 5 mice per group). (A) Proportions of CD4 and IFN-–expressing TH1 cells in the colon were analyzed by flow cytometric analysis. (B) IL-12 secretion levels 
in the serum were measured by CBA analysis. (C) Primary CD4+ T cells were isolated from human cord blood and cultured in the presence of anti-CD3/28 microbeads and 
GQDs for 2 days, and proliferation was assessed with a BrdU assay. OD, optical density. (D to G) Human primary CD4+ T cells were induced to differentiate into TH1 cells 
using anti-CD3/28 beads in combination with recombinant IL-2, IL-12, and IFN- in the presence of GQDs for 5 days. (D and E) The proportion of CD4+IFN-+ cells was 
determined by flow cytometric analysis. (D) Representative dot plot images. (E) Histogram of collective data. (F) mRNA expression levels in each group of induced TH1 cells 
were investigated for the indicated TH1-specific markers. (G) The indicated TH1-specific cytokines in the supernatant of TH1 cells were analyzed by CBA analysis (n = 4 to 5). 
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GQDs specifically promote polarization of M2b subtype, 
leading to the increased infiltration of Tregs
Given that the infiltration of colonic Tregs was increased and that M2- 
converted macrophage promoted the development of Tregs (Fig. 6D), 
GQDs have a potential role in the formation of a reciprocal regula-
tory loop of Tregs and intestinal macrophages via IL-10 and TGF-1 
signaling.
M2 macrophages are categorized into at least three different pop-
ulations that have distinct cellular characteristics, gene profiles, and 






































































































































Fig. 5. The effects of GQDs on cell fate decisions of Tregs and TH17 cells. (A, D, and F to H) The GQD-treated mice with chronic colitis were sacrificed, and colons and 
serum samples were collected for further ex vivo examination (N = 4 to 5 mice per group). (A) Colonic infiltration of CD4+CD25+FoxP3+ Tregs was assessed by flow cytometric 
analysis. (B and C) The GQD-treated mice with acute colitis were sacrificed, and colons were collected for further ex vivo examination (N = 8 to 12 mice per group). DAPI, 
4′,6-diamidino-2-phenylindole. (B) Tregs in the colon were observed by immunostaining of FoxP3 (green). FoxP3+ cells are indicated as arrows. Scale bar, 50 m. (C) TGF-1 
expression in the colons was detected by ELISA. (D) IL-10 level was determined by CBA analysis. (E) CD4+ T cells were isolated from human cord blood, polarized into Tregs 
with specific cytokines, and the proportions of CD4+CD25+FoxP3+ cells were determined by flow cytometric analysis (n = 5). (F) Proportions of TH17 cells in the spleens were 
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(24). Among these cells, M2a and M2b macrophages appear to ex-
hibit immunoregulatory activities, while M2c macrophages are re-
sponsible for immunosuppressive activities and tissue remodeling 
(25). Interactions between the macrophage subtypes and graphene 
derivatives have not been previously elucidated. As IL-10 expres-
sion was increased, whereas the M2a markers CLEC7A and IL-1ra 
were reduced (fig. S7B), GQDs could up-regulate specific subtypes 
of M2 macrophages. To address the issue, we differentiated naïve 
CD14+ cells into M2a, M2b, and M2c macrophages in the presence 
of GQDs. The expression of CD206 and CD163 on M2a macro-
phages was markedly reduced, while there was no notable change in 
M2c subtype cells (fig. S7C). Notably, the expression of CD86 and 
C













































































































Fig. 6. GQDs promote M2 polarization of macrophages. (A and B) Primary CD14+ macrophage-like cells were polarized into M1-type cells. (A) CD14+ macrophage-like 
cells were isolated from human cord blood and polarized into M0-, M1-, and M2-type cells with specific inducer cytokines in the presence of GQDs. The cells were 
immuno stained for the cell surface markers CD14 and CD206. Scale bar, 50 m. (B) M1-polarized macrophages were analyzed by the type-specific cell surface CD markers 
CD86, CD206, and CD163 using flow cytometry. (C) The indicated cytokine concentrations were measured in supernatants of M1 macrophages. (D) M1-induced cells in the 
presence of GQDs were cocultured with naïve CD4+ T cells supplemented with IL-2 and TGF-1, and the proportions of Tregs were investigated by flow cytometry. (E) In vitro 
M2b polarization was analyzed by flow cytometric analysis (n = 3). (F) The presence of M2b macrophages in the peritoneum of chronic colitis–induced mice was detected 
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CD206 on macrophages in M2b polarizing conditions was elevated 
(Fig. 6E). Coherently, the proportion of M2b-subtype macrophages 
was increased by GQD treatment in DSS-induced mice (Fig. 6F). 
Therefore, GQDs decreased the expression of M2a cell surface mark-
ers, while M2c cells did not experience any notable changes. The pro-
portions of M2b-subtype cells in vitro and in vivo were increased in 
response to GQD treatment. In summary, among M2-type cells, M2b 
macrophages were directly influenced and were responsible for mo-
bilizing Tregs at the colon in an inflammatory milieu.
DISCUSSION
GQDs recovered intestinal immune homeostasis by suppressing ex-
cessive inflammation and facilitating the development of a regu-
latory loop of T cells. Intestinal macrophages, as a key regulator of 
immune tolerance, control gut homeostasis and protect tissues against 
excessive immune responses by maintaining the functionality of Tregs 
(23). Moreover, alternatively activated M2 macrophages also have 
critical roles in tissue repair (26). The ability of GQDs to mediate po-
larization of macrophages is less clear, and the current findings are 
controversial: While several studies have reported that graphene oxide 
(GO) treatment directed macrophage polarization to the M1 type in a 
size-dependent manner (27), others found that GO scaffolds increased 
the infiltration of M2-type cells (28). Using the report of Ma et al. 
(27) on the immunostimulatory function of GOs, we found that GQDs 
activate M0 cells to polarize toward the M1-type and suppress M2-
type cell development. More importantly, GQDs exert potent immu-
nosuppression in inflammatory environments in vitro and in vivo by 
converting M1 into M2 macrophages, which is consistent with the 
study of Nishida et al. (28). In line with previous reports, we also 
found that GQDs alleviate colitis in mice by polarizing macrophages 
into M2 type and resulting in an increase of Treg development.
The underlying mechanism of GQDs on immunosuppression is 
still under research; however, we could interpret the mode of ac-
tions based on its structure. As GQDs have a conjugated graphitic 
domain and abundant hydrogen-donating functional groups on the 
edges, they are well known for their potent antioxidant effect. Be-
cause inflammation is associated with the imbalance between oxi-
dative stress and antioxidants, GQDs’ ability to scavenge reactive 
oxygen species (ROS) can assist in regulating inflammation. We 
also found that GQD treatment decreases the ROS level in THP-1 
macrophages (fig. S8A). GQDs inhibited IFN- secretion in THP-1 
cells, as we observed in primary macrophages (fig. S8B). At the same 
time, GQDs increased M2 marker–expressing cells, as shown by 
N-acetylcysteine (NAC), which is known as ROS scavenger (fig. S8C). 
This finding implies that GQDs regulate ROS in proinflammatory M1 
macrophages, resulting in M2 polarization of macrophages.
Besides the antioxidant effect of GQDs, inflammatory cytokines 
such as TNF- and IL-10, which are known to be in correlation with 
the ROS level, were regulated by GQDs. On the basis of the previous 
research, elevating the superoxide dismutase level through genetic 
modification could substantially ameliorate DSS-induced colitis (29). 
TNF-, a proinflammatory cytokine produced from CD4+ cells and 
M1 macrophages, is known to induce ROS generation, and the treat-
ment of antioxidants can decrease the ROS-derived damages (30). In 
the presence of GQDs, the TNF- level decreased significantly, there-
fore inhibiting further oxidative damage by ROS production.
In the absence of IL-10, colitis can be induced through robust 
intestinal inflammation (31), and research on regulating IL-10 level 
in IBD patients as a therapeutic target has been carried on (32). IL-10 
inhibits the production of ROS from the macrophage, and by treating 
NAC, remarkable improvements in the DSS-induced colitis disease 
was observed (33). By treating GQDs, the level of IL-10 was highly 
elevated, showing the potential to function as a therapeutic strategy.
Another factor to consider is that GQDs have a negative surface 
charge due to carboxyl and hydroxyl groups. The research on the 
effect of nanoparticle’s surface charge on inflammation and immuno-
regulation has been carried on, and many studies revealed that 
negatively charged nanoparticles are less prone to provoke immuno-
stimulation (10). As the leading treatment target of colitis is to 
ameliorate excessive immune responses, injected particles must not 
induce additional stimulation on the immune system.
Although these findings suggest that the properties of GQDs, in-
cluding the lateral size, height, and functional groups, are suitable 
for the use in a clinical application against colitis, it needs to be fur-
ther investigated whether modifications to GQDs, such as changes to 
the surface charge, the ratio between functional groups, or addition of 
a bactericidal effect to the materials, may cause different therapeutic 
outcomes (34). In addition to this, various animal models, such as 
IL-10 knockout or CD45 T cell–transferred mice, and consequentially 
clinical trials can be envisioned for challenging the feasibility.
Despite the fact that GQDs were found in the abdominal cavity, 
when GQDs are intraperitoneally or intravenously injected, they are 
distributed through the whole organs and are mainly accumulated 
in the liver and spleen (35). In line with the previous study, we found 
that injected GQDs preferred to accumulate on greater omentum 
and mesentery near spleen and colon. Then, the particles are mostly 
excreted through urine or removed by hepatocytes in the liver through 
endocytosis (36). Also, as GQDs are composed of the hydrophobic 
graphitic domain and hydrophilic functional groups, and due to 
their small size, luminal uptake through endocytosis is probable (37). 
Besides the clearance of GQDs through urine, enzymes such as MPO 
and horseradish peroxidase are known to degrade GQDs (38). Once 
they are degraded and become smaller particles, it is much easier to 
be cleared out through the kidney, as particles smaller than 5 nm are 
proved to be rapidly excreted through urine (39). Therefore, GQDs 
could be cleared out naturally without generating noticeable toxicity. 
Nevertheless, validation of the therapeutic efficiency of GQDs via 
oral administration remains to be determined for actual therapeutic 
use in practice. With oral administration, the effect of GQDs can be 
relatively limited to a specific organ, reducing systemic side effects 
that appeared by any chance.
Overall, intraperitoneally injected GQDs attenuated intestinal 
inflammation in both acute and chronic DSS-induced experimental 
colitis models. GQDs effectively regulated excessive immune responses 
and prevented tissue damage by indirectly inducing colonic and splenic 
infiltration of Tregs and converting classical macrophages (M1) to alter-
native macrophages (M2), particularly the M2b subtype, in the pro-
inflammatory milieu. With negligible toxicity and natural clearance, 
GQDs were able to maintain intestinal immune homeostasis, showing 
a potency to be used in treating IBDs.
MATERIALS AND METHODS
Preparation of GQDs
First, pristine GOs were synthesized through the improved Hummer’s 
method (15). To prepare GQDs, the obtained solution of GOs in de-









Lee et al., Sci. Adv. 2020; 6 : eaaz2630     29 April 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
10 of 13
vacuum- filtered with cellulose nitrate membrane filter (0.45 m; GE 
Healthcare Life Science, Buckinghamshire, UK).
Biotinylation of GQDs
The biotinylation of GQDs was achieved by 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) coupling. First, 10 mg of N-(3-dimethylaminopropyl)- 
N′-ethylcarbodiimide hydrochloride, EDC reagent (Sigma-Aldrich, 
St. Louis, MO, USA), was added to 10 ml of GQD solution (3 mg/ml) 
to replace the edge carboxyl groups with EDC reagents. After 
30 min, 20 mg of Amine-PEG3-Biotin (Thermo Fisher Scientific, 
San Jose, CA, USA) was subsequently added to the solution to form 
amide bonds between activated edges of GQDs, and reactive amine 
groups of biotin for 24 hours. The solution was then dialyzed with 
a 1-kD molecular weight cut-off nitrocellulose membrane bag 
(Thermo Fisher Scientific, Hampton, NH, USA) to discard unreacted 
EDC and biotin molecules. The concentration of the final product 
was measured by obtaining powder after freeze-drying small amount 
of the solution.
TEM imaging
The sample solutions (10 g/ml) were adsorbed to 300 mesh lacey 
carbon-coated copper grids (Ted Pella Inc., Redding, CA, USA) for 
30  min. The grids were rinsed with a few drops of DI water and 
thoroughly dried in a desiccator before imaging. The samples were 
analyzed by a high-resolution TEM (JEM-3010, JEOL Ltd.), and the 
images were collected with a Gatan digital camera (MSC-794) cou-
pled to the microscope.
Atomic force microscopy
The GQD sample was prepared on a silicon wafer and was measured by 
XE-100 AFM (Park Systems, Suwon, Republic of Korea) by noncontact 
mode. The image size of 25 m2 was obtained at a scan rate of 0.8 Hz.
Raman spectroscopy
The powder products were prepared on SiO2 substrates for the Raman 
spectra measurements. The spectra were obtained with a Renishaw 
micro-Raman spectrometer with 514.5-nm Ar excitation laser.
FT-IR spectroscopy
Before the FT-IR spectra measurements, the powder samples were 
fully dried in a desiccator to prevent undesirable oxygen-containing 
peaks. The spectra were measured by the conventional KBr pellet 
method (Nicolet 6700, Thermo Fisher Scientific).
Elemental analysis
The GQD powder was obtained by freeze-drying the solution and was kept 
in a desiccator for more than 3 days to avoid contamination from other 
elements. The weight percentage of each elements was measured with an 
automatic elemental analyzer (FLASH 2000, Thermo Fisher Scientific).
X-ray photoelectron spectroscopy
The GQD powder was prepared by the same method as for element 
analysis. The binding energy of C1s was measured by XPS (AXIS-HSi, 
KRATOS).
Zeta potential
The GQD solution (50 g/ml) was filtered with a 200-nm syringe filter, 
and the zeta potential was measured using Zetasizer Nano ZS (Malvern 
Instruments Ltd, Malvern, UK).
Animals
All animal experiments were carried out in accordance with the ap-
proved guidelines of Seoul National University Institutional Animal 
Care and Use Committee (IACUC no. SNU-170523-4). For induction 
of acute colitis, 6-week-old male C57BL/6 mice (Orientbio, Sungnam, 
Republic of Korea) were grouped randomly and given 3% DSS in 
drinking water for 7 days (16 mice per group). On day 1, one day after 
DSS induction, the mice were injected intraperitoneally with GQDs 
(15 mg/kg). Chronic experimental colitis was induced by repetitive 
administration of 3.5% DSS solution and fresh water. The body weights 
of the mice were measured daily, and the DAI, which is composed of 
body weight loss, activity, stool consistency, bleeding, and hair condition, 
was evaluated on day 10 for the acute model and on day 27 for the 
chronic model. After the mice were anesthetized, spleens, large intestines, 
and blood samples were collected for more ex vivo examinations.
Histopathological evaluation
Colon samples were fixed in 10% formalin for more than 24 hours 
and were processed following a typical method, including dehydration 
with ethanol, clearing with xylene, and wax infiltration with paraffin. 
Paraffin-embedded blocks were sectioned to 5-m thickness and 
stained with hematoxylin and eosin (H&E), Masson’s trichrome, 
and picrosirius red. Loss of goblet cells, hyperemia/edema, infiltra-
tion of immune cells, the presence of crypt abscesses, and loss of 
epithelium were scored on a histopathological index by H&E stain-
ing. The area of fibrotic tissue was measured by Masson’s trichrome 
staining for the acute model and by picrosirius red for the chronic 
model and was quantified using ImageJ software version 1.46r (U.S. 
National Institutes of Health, Bethesda, MD, USA).
Cytokine detection
To determine the secretion levels of various cytokines, serum sam-
ples isolated from blood and culture supernatants of cells were pre-
pared. To measure levels of cytokines in vivo, the Cytometric Bead 
Array (CBA) Kit for Mouse Inflammation (BD Biosciences, San Jose, 
CA, USA), the CBA flex for IL-17A and IL-23 (BD Biosciences), and 
enzyme-linked immunosorbent assay (ELISA) kits for MPO (R&D Sys-
tems, Minneapolis, MN, USA) and TGF-1 (Thermo Fisher Scientific) 
were used according to the manufacturer’s protocols. The CBA Kit for 
TH1/TH2/TH17 (BD Biosciences) was used to evaluate cytokine secre-
tion of the primary immune cell–induced specific lineages in vitro. The 
results were detected using flow cytometry and a spectrophotometer.
In vivo safety and toxicity evaluation of GQDs
To determine safety and possible toxicity, 300 g of GQDs (per head, 
15 mg/kg) was intraperitoneally infused and monitored for 16 weeks. 
The body weights and amount of intake (feed and water) per day were 
assessed at designated time points. After mice were sacrificed, weights of 
major organs were measured, and the composition of immune cells in the 
spleen was determined by flow cytometric analysis. To examine the level 
of proinflammatory cytokines, blood samples were collected, and we 
conducted CBA analysis according to the manufacturer’s instructions.
Tracking of GQDs
For in vivo trafficking and analysis of excretion levels, biotinylated 
GQDs were intraperitoneally infused. To determine the remaining 
amounts of GQDs, mesentery tissue was collected after mice were 
sacrificed. After the tissue was minced and homogenized, it was in-
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Fluorescence was assessed using flow cytometric analysis. In addi-
tion, urine samples were also collected at designated time points to 
investigate excretion as described in a previous report (14). The 
concentrations of the GQDs in urine samples were measured by the 
Quant*Tag Biotin Kit (Vector Laboratories Inc., Burlingame, CA, USA).
Isolation and culture of human mononuclear cells
All experimental procedures involving hUCB-derived cells were car-
ried out in accordance with the approved guidelines of the Boramae 
Hospital Institutional Review Board (IRB) and the Seoul National 
University IRB (IRB no.1707/001-008). hUCB-mononuclear cells were 
isolated and cultured as previously described (18). Briefly, UCB sam-
ples were collected immediately after delivery with informed consent 
and parental approval. The UCB samples were mixed with HetaSep 
solution (STEMCELL Technologies, Vancouver, Canada) at a ratio of 
5:1 and incubated at room temperature for 1 hour. Then, the super-
natant was collected with Ficoll, and mononuclear cells were separated 
after centrifugation at 2500 rpm for 20 min. The cells were washed 
twice in PBS. Using the isolated cells, other experimental processes 
were conducted for further in vitro analyses.
Isolation and polarization of T cells
Naïve CD4+ T cells were separated from freshly isolated hUCB-
MNCs with the Human Naïve CD4+ T Cell Isolation Kit II (Miltenyi 
Biotec, Bergisch Gladbach, Germany) according to the manufacturer’s 
instructions. Naïve CD4+ T cells were cultured in RPMI 1640 (Gibco- 
BRL, Grand Island, NY, USA) supplemented with 10% of fetal bovine 
serum (FBS), anti-CD3/28 bead activator, and IL-2 (20 ng/ml), which 
were essential for the proliferation of the T cell subsets. To differen-
tiate the cells toward T cell subtypes, type-specific cytokines were 
added to the growth medium [IFN- (20 ng/ml) and IL-12 (20 ng/ml) 
for type 1 helper T cells and TGF-1 (20 ng/ml) for Tregs], and cells 
were cultured for 5 days at 37°C in a humidified atmosphere with 
5% CO2 in the presence/absence of GQDs. Polarized TH1 and Tregs 
were verified with type-specific staining and flow cytometry. For TH1 
cells, surface staining with CD4 antibody was followed by intracel-
lular staining for IFN-, while CD4, CD25, and FoxP3 antibodies were 
used for the Treg analysis.
Isolation and polarization of macrophages
Macrophages were separated from freshly isolated hUCB-MNCs with 
the Human CD14+ Monocyte-like Cell Isolation Kit (Miltenyi Biotec, 
Bergisch Gladbach, Germany) according to the manufacturer’s in-
structions. CD14+ monocyte-like cells were cultured in RPMI 1640 
(Gibco-BRL) supplemented with 10% FBS and stabilized for 2 days 
with GM-CSF (granulocyte-macrophage colony-stimulating factor) 
for M1 and with M-CSF (macrophage colony-stimulating factor) for 
M2. To polarize the cells toward macrophage subtypes, type-specific 
cytokines were added to the growth medium [M1: IFN- (20 ng/ml) and 
lipopolysaccharide (LPS) (1 g/ml); M2a: IL-4 (20 ng/ml) and IL-13 
(20 ng/ml); M2b: LPS (1 g/ml), polyinosinic:polycytidylic acid 
(Poly I:C) (10 g/ml), and IL-1 (20 ng/ml); M2c: IL-10 (20 ng/ml) 
and TGF-1 (20 ng/ml)], and cells were cultured for 5 days at 37°C 
in a humidified atmosphere with 5% CO2 in the presence/absence of 
GQDs. To verify the effects of graphene derivatives on the polariza-
tion of macrophages, flow cytometry and immunostaining were used. 
A CD14 antibody was used as an overall macrophage marker, and 
antibodies against CD86, CD163, and CD206 were applied as spe-
cific markers for M1 and M2 subtypes. Primary M1-polarized mac-
rophages in the presence of GQDs were subsequently cocultured with 
naïve CD4+ T cells supplemented with the Treg-specific growth factors 
IL-2 and TGF-1.
Cell proliferation assay
To measure the proliferation of the cells, the Cell Proliferation ELISA 
Kit (Roche, Indianapolis, IN, USA) was used according to the manu-
facturer’s instructions. The bromodeoxyuridine (BrdU) cell prolifer-
ation assay was conducted as previously described (18). Briefly, the 
cells were incubated with 100 M of BrdU-labeling reagent for 2 hours 
at 37°C in a humidified atmosphere with 5% CO2. After 30 min of fixa-
tion with the provided FixDenat solution, the cells were incubated in 
anti-BrdU antibody solution for 90 min and in the provided substrate 
(tetramethylbenzidine) solution for 5 to 30 min at room temperature. 
After pouring stop solution into each well, the level of cell prolifera-
tion was quantified by measuring the absorbance at wavelengths of 
450 and 690 nm (as a reference).
Quantitative reverse transcription polymerase  
chain reaction
Total RNA was extracted using TRIzol (Invitrogen, Carlsbad, CA, 
USA) according to the manufacturer’s instructions. The acquired 
RNA was used to synthesize complementary DNA (cDNA) by the 
SuperScript First-Strand Synthesis System (Invitrogen). The relative 
expression levels of target mRNAs were measured using SYBR Green 
PCR Master Mix (Applied Biosystems, Foster City, CA, USA) with an 
ABI 7300 detection system. At least three independent analyses were 
conducted for each gene. Detailed information for primers were de-
scribed in table S2.
Cell cycle assay
Cells were fixed with ice-cold 70% ethanol at −20°C for more than 
30 min. The fixed cells were washed in PBS and incubated with 400 l 
of PBS containing ribonuclease A (RNase A; 7.5 g/ml) and propidium 
iodide (PI) (50 g/ml) at 37°C for 30 min. Cell cycles were analyzed 
by flow cytometry, which was performed on a FACSCalibur using 
CellQuest software (BD Biosciences).
Apoptosis assay
Cells were stained with 5 l of FITC annexin V and 5 l of PI using 
Apoptosis Detection Kits (BD Biosciences). The mixtures were gently 
vortexed and incubated for 15 min at room temperature in the dark. 
Then, 400 l of 1× binding buffer was added to the mixtures, and all 
samples were analyzed by flow cytometry, which was performed on 
a FACSCalibur using CellQuest software (BD Biosciences).
Immunofluorescence analysis
Cells were fixed with 4% paraformaldehyde in PBS for 15 min at 
room temperature and were then permeabilized with 0.25% Triton 
X-100 (Sigma-Aldrich) for 10 min. The fixed cells were incubated with 
blocking solution (5% normal goat serum) for 1 hour at room tem-
perature and incubated with primary antibodies overnight at 4°C. 
The cells were incubated with secondary antibodies labeled with Alexa 
Fluor 488 and 594 (Invitrogen). 4′,6-Diamidino-2- phenylindole (DAPI; 
Sigma-Aldrich) staining was conducted for 5 min to stain nuclei.
For whole-tissue immunofluorescence, the paraffin slides were 
deparaffinized and then blocked with PBS containing 5% normal 
goat serum. The sections were incubated with primary antibodies 
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(Invitrogen) followed by DAPI staining. Images were captured using 
a confocal microscope (Eclipse TE200, Nikon, Japan).
ROS measurements
THP-1 cells were treated with 100 nM phorbol 12-myristate 13-acetate 
(PMA) for 24 hours and then treated with IFN- (20 ng/ml) and 
LPS (1 g/ml) with or without GQDs for 24 hours. After washing 
the cells with PBS, the medium was changed to serum-free Dulbecco’s 
modified Eagle’s medium (DMEM) containing 20 M H2DCFDA 
(Invitrogen) at 37°C. Thirty minutes after the treatment, cells were 
washed and collected to be analyzed using flow cytometry, which 
was performed on a FACSCalibur using CellQuest software (BD 
Biosciences).
THP-1 differentiation
THP-1 cells were treated with 100 nM PMA for 24 hours and then 
treated with IFN- (20 ng/ml) and LPS (1 g/ml) with or without 
GQDs for 24 hours. NAC (8 mM) was treated before the PMA treat-
ment for 1 hour, and 1 M H2O2 was treated with IFN- and LPS 
for 24 hours.
Statistical analysis
The results are expressed as means ± SD. Statistical analyses were 
conducted using Student’s two-tailed t test or one-way analysis of 
variance (ANOVA) followed by the Bonferroni post hoc test for 
multigroup comparisons using GraphPad Prism version 8.0 (GraphPad 
Software, San Diego, CA, USA). Statistical significance is indicated 
in the figure legends.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/18/eaaz2630/DC1
View/request a protocol for this paper from Bio-protocol.
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